Advancements in molecular techniques have allowed researchers to subgroup different breast cancers, giving rise to luminal A, luminal B, HER2-positive and triple-negative breast cancer (TNBC) [60]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.